A Phase 3 interventional study of AXS-05 and Placebo in Depression and Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,713 studies in Depression with a site in United States — 582 open to participants now, 720 under way, 30 of them phase 3. Depression · United States.
Among the 3,713 studies in Depression with a site in United States, this one is the 501st largest by enrollment of the 3,320 interventional ones that give a count, is one of 184 that started in 2019, is one of 237 in phase 3, and was the 2,225th registered.
8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.
Browse Depression studies →582 of the 3,713 studies in Depression with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
NeuroRx, Inc. · Sites in United States
Ages 18–80
University of Michigan · Sites in United States
Ages 13+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,713 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 235 · Phase 2 441 · Phase 3 285 · Phase 4 265
First in 1977; this study’s year is marked. 184 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 327 is above the median of 81 across 7,078 interventional studies indexed under Depression.
Median enrollment 72 across the 3,320 interventional studies, 138 across the 371 observational. Of the 2,762 that completed or were terminated, 1,045 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
392 of 3,713 have an industry lead sponsor. The 10 most frequent:
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Axsome Therapeutics, Inc. has 7 studies filed under Depression — fewer than ten, so there is no comparison to draw.
299 of the studies in Depression with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT05474846Phase 3M.D. Anderson Cancer CenterCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | 2027-02-28 |
| NCT04777357Phase 3AbbVieA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | 2027-03 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 299 to your calendar (.ics) → With an account.
Among the 3,713 studies in Depression with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
This study will evaluate AXS-05 in a randomized, double-blind, placebo-controlled study in patients with MDD. Eligible patients will be randomized in a 1:1 ratio to treatment with AXS-05 or placebo for 6 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AXS-05 (bupropion and dextromethorphan) oral tablets
Drug: AXS-05
Placebo oral tablets to match AXS-05
Drug: Placebo
Oral AXS-05 tablets, taken daily for 6 weeks.
Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
Change in MADRS Total Score From Baseline to Week 6
The primary objective of the study was to evaluate the efficacy of AXS-05 as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms from baseline to Week 6. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.
Time frame: 6 weeks
| Milestone | AXS-05 | Placebo |
|---|---|---|
| Started | 163 | 164 |
| Completed | 123 | 147 |
| Not completed | 40 | 17 |
The primary objective of the study was to evaluate the efficacy of AXS-05 as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms from baseline to Week 6. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.
| score on a scale | AXS-05 | Placebo |
|---|---|---|
| Change in MADRS Total Score From Baseline to Week 6 | 15.91 ± 0.921 | 12.04 ± 0.862 |
Collected over Treatment-emergent adverse events (TEAEs) were AEs with an onset date on or after the date of first dose. TEAEs were collected through 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AXS-05 | 0/162 (0%) | 1/162 (0.6%) | 100/162 (61.7%) |
| Placebo | 0/164 (0%) | 0/164 (0%) | 74/164 (45.1%) |
| Event | AXS-05 | Placebo |
|---|---|---|
| PancreatitisGastrointestinal disorders | 1/162 | 0/164 |
| Event | AXS-05 | Placebo |
|---|---|---|
| All Others, occurring in <5% of SubjectsGeneral disorders | 47/162 | 43/164 |
| DizzinessNervous system disorders | 26/162 | 10/164 |
| NauseaGastrointestinal disorders | 21/162 | 14/164 |
| HeadacheNervous system disorders | 13/162 | 6/164 |
| DiarrheaGastrointestinal disorders | 11/162 | 5/164 |
| SomnolenceNervous system disorders | 11/162 | 5/164 |
| Dry mouthGastrointestinal disorders | 9/162 | 4/164 |
Participants randomized
| Age, Continuous(years) | AXS-05 | Placebo | Total |
|---|---|---|---|
| Mean | 42.1 ± 12.71 | 41.1 ± 13.78 | 41.6 ± 13.25 |
| Sex: Female, Male(Participants) | AXS-05 | Placebo | Total |
|---|---|---|---|
| Female | 98 | 117 | 215 |
| Male | 65 | 47 | 112 |
| Race (NIH/OMB)(Participants) | AXS-05 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 9 | 8 | 17 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 61 | 55 | 116 |
| White | 88 | 92 | 180 |
| More than one race | 3 | 3 | 6 |
| Unknown or Not Reported | 0 | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Nov 2019, 5 months.
Results were first posted in Oct 2022, 2 years 10 months after primary completion. A results delay was requested in Dec 2020.
Of 81 phase 3 interventional studies under Depression, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05